Hong Kong Stock Surge: IMMUNEONCO-B Soars Over 7% on Positive IMM2510 Data for IO-Refractory Lung Cancer

Stock News

Jun 02

IMMUNEONCO-B (HKEX: 01541) experienced a significant rise of over 7% in its share price.

At the time of writing, the stock was up 7.36%, trading at HK$3.21 with a turnover of approximately HK$26.71 million.

IMMUNEONCO-B (HKEX: 01541)

The catalyst for the movement was a company announcement regarding its proprietary VEGF×PD-L1 bispecific drug candidate, Pervelafusp α (IMM2510).

On June 1st, the company presented Phase I clinical trial data for IMM2510 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The data, from Abstract #8580, demonstrated that IMM2510 showed significant efficacy and a favorable safety profile distinct from similar products in patients with advanced squamous non-small cell lung cancer who had progressed after prior immunotherapy.

Based on the positive Phase I data and exposure-response analysis, the study has established 20mg/kg administered every two weeks as the recommended Phase II dose.

The company indicated that planning for subsequent Phase III clinical studies is now underway.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1111280265"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111280265\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111280265?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 15:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111280265","market":"nz","top_or_hot":-1,"title":"Hong Kong Stock Surge: IMMUNEONCO-B Soars Over 7% on Positive IMM2510 Data for IO-Refractory Lung Cancer","media":"Stock News","content":"<p>IMMUNEONCO-B (HKEX: 01541) experienced a significant rise of over 7% in its share price.<br><br>At the time of writing, the stock was up 7.36%, trading at HK$3.21 with a turnover of approximately HK$26.71 million.<br><br><b>IMMUNEONCO-B (HKEX: 01541)</b><br><br>The catalyst for the movement was a company announcement regarding its proprietary VEGF×PD-L1 bispecific drug candidate, Pervelafusp α (IMM2510).<br><br>On June 1st, the company presented Phase I clinical trial data for IMM2510 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.<br><br>The data, from Abstract #8580, demonstrated that IMM2510 showed significant efficacy and a favorable safety profile distinct from similar products in patients with advanced squamous non-small cell lung cancer who had progressed after prior immunotherapy.<br><br>Based on the positive Phase I data and exposure-response analysis, the study has established 20mg/kg administered every two weeks as the recommended Phase II dose.<br><br>The company indicated that planning for subsequent Phase III clinical studies is now underway.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Surge: IMMUNEONCO-B Soars Over 7% on Positive IMM2510 Data for IO-Refractory Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Surge: IMMUNEONCO-B Soars Over 7% on Positive IMM2510 Data for IO-Refractory Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-02 15:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B (HKEX: 01541) experienced a significant rise of over 7% in its share price.<br><br>At the time of writing, the stock was up 7.36%, trading at HK$3.21 with a turnover of approximately HK$26.71 million.<br><br><b>IMMUNEONCO-B (HKEX: 01541)</b><br><br>The catalyst for the movement was a company announcement regarding its proprietary VEGF×PD-L1 bispecific drug candidate, Pervelafusp α (IMM2510).<br><br>On June 1st, the company presented Phase I clinical trial data for IMM2510 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.<br><br>The data, from Abstract #8580, demonstrated that IMM2510 showed significant efficacy and a favorable safety profile distinct from similar products in patients with advanced squamous non-small cell lung cancer who had progressed after prior immunotherapy.<br><br>Based on the positive Phase I data and exposure-response analysis, the study has established 20mg/kg administered every two weeks as the recommended Phase II dose.<br><br>The company indicated that planning for subsequent Phase III clinical studies is now underway.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1111280265","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111280265","pubTimestamp":1780384707,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (HKEX: 01541) experienced a significant rise of over 7% in its share price.At the time of writing, the stock was up 7.36%, trading at HK$3.21 with a turnover of approximately HK$26.71...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","01541":"宜明昂科-B"},"translate_title":"港股大涨：IMMUNEONCO-B因IMM2510治疗IO难治性肺癌数据阳性而飙升超7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"01541":1},"content_text":"IMMUNEONCO-B (HKEX: 01541) experienced a significant rise of over 7% in its share price.At the time of writing, the stock was up 7.36%, trading at HK$3.21 with a turnover of approximately HK$26.71 million.IMMUNEONCO-B (HKEX: 01541)The catalyst for the movement was a company announcement regarding its proprietary VEGF×PD-L1 bispecific drug candidate, Pervelafusp α (IMM2510).On June 1st, the company presented Phase I clinical trial data for IMM2510 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.The data, from Abstract #8580, demonstrated that IMM2510 showed significant efficacy and a favorable safety profile distinct from similar products in patients with advanced squamous non-small cell lung cancer who had progressed after prior immunotherapy.Based on the positive Phase I data and exposure-response analysis, the study has established 20mg/kg administered every two weeks as the recommended Phase II dose.The company indicated that planning for subsequent Phase III clinical studies is now underway.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}